Please assess the completion status of the following clinical trial:

Trial Title: Replacement of Lamivudine by Telbivudine to Improve Renal Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Sign inform consent~2. Age is not less than 16 years old.~3. Post liver transplantation patient for HBV-related indication.~4. Chronic hepatitis B transplant patients who are treated by lamivudine for not less than 6 months.~5. eGRF stage 2-4 patients (15\<eGFR\<90ml)~6. Stable liver function, ALT not more than 2 folds of upper limit.~Exclusion Criteria:~1. Acute rejection with increase CNI dose within a month.~2. Pregnant or nursing.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Lamivudine group (Type: NO_INTERVENTION): continue Lamivudine
- Telbivudine group (Type: EXPERIMENTAL): Telbivudine replaces Lamivudine

Based on this trial design, predict the completion outcome and termination type (if applicable).